本页面由Tiger Trade Technology Pte. Ltd.提供服务

Avalo Therapeutics Inc

12.01
-1.2300-9.29%
盘后:12.010.00000.00%16:40 EDT
成交量:164.90万
成交额:2,040.10万
市值:6.44亿
市盈率:-2.72
高:13.23
开:13.23
低:11.99
收:13.24
52周最高:24.27
52周最低:11.99
股本:5,363.00万
流通股本:4,014.95万
量比:2.16
换手率:4.11%
股息:- -
股息率:- -
每股收益(TTM):-4.4100
每股收益(LYR):-5.8400
净资产收益率:-36.27%
总资产收益率:-18.50%
市净率:1.44
市盈率(LYR):-2.06

数据加载中...

2026/07/06

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/06/23

重要事件披露

Form 8-K - Current report
2026/06/18

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/06/16

重要事件披露

Form 8-K - Current report
2026/06/12

重要事件披露

Form 8-K - Current report
2026/06/08

重要事件披露

Form 8-K - Current report
2026/06/05

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/06/02

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/29

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/26

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/15

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/15

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/15

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/13

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/05/13

重要事件披露

Form 8-K - Current report